SIVmac239 at 18 amino acid positions in gpl20 and at 5 and 10 amino acid positions, respectively, in gp4l.
Sequential sera from the monkey infected with cloned SIVmac239 from which the 1-12 and 8-22 variants were isolated showed much higher neutralizing antibody titers to cloned SIVmac239 than to the cloned 1-12 and 8-22 variants. For example, at 55 weeks postinfection the neutralizing antibody titer against SIVmac239 was 640 while those to the variant viruses were 40 and less than 20. Two other rhesus monkeys infected with cloned SIVmac239 showed a similar pattern. Rhesus monkeys were also experimentally infected with the cloned variants so that the type-specific nature of the neutralizing antibody responses could be verified. Indeed, each of these monkeys showed neutralizing-antibody responses of much higher titer to the homologous variant used for infection. These experiments unambiguously demonstrate that SIV mutants resistant to serum neutralization arise during the course of persistent infection of rhesus monkeys.
Simian immunodeficiency virus (SIV) is a member of the lentivirus subfamily of retroviruses. This group also includes human immunodeficiency virus (HIV), equine infectious anemia virus (EIAV), visna virus, and caprine arthritisencephalitis virus. Members of the lentivirus subfamily establish long-term, persistent infections resulting in chronic, nononcogenic, debilitating disease.
Antigenic variation during persistent infection has been documented in at least three lentivirus systems, EIAV (22, 23, 32, 41, 42, 47) , visna virus (9, 27, 36-39, 43, 50) , and caprine arthritis-encephalitis virus (10, 40) . The strongest evidence for immune selection lies in the EIAV system, in which disease is characterized by recurrent clinical episodes of fever, hemolytic anemia, bone marrow depression, lymphoproliferation, immune-complex glomerulonephritis, and persistent viremia (32) . Plasma recovered from an infected animal can effectively neutralize virus isolated from earlier febrile episodes but cannot neutralize virus isolated during subsequent febrile episodes (23, 32, 47) . The animals in these j Present address: Department of Molecular and Cellular Biology, SmithKline Beecham Biologicals, B-1330 Rixensart, Belgium. studies thus exhibited delayed neutralizing-antibody responses against variant viruses. By inoculating horses with variant strains of EIAV, type-specific neutralizing-antibody responses have been generated against variant viruses (23) . Sequence changes responsible for the resistance of variants to serum neutralization have not been defined.
The emergence of neutralization resistant HIV-1 variants in HIV-1 infected chimpanzees (35) and in an HIV-1 infected human (51) has been reported. Sera for neutralization tests were derived from the individual in which the variants emerged. These experiments were performed in one direction only since additional sera from individuals naturally or experimentally infected with variant virus were not available for reciprocal testing of neutralizing activity. This is problematic since different virus stocks show considerable variation in the efficiency with which they score in neutralization tests (25, 28) . Such inherent differences in the efficiencies with which virus stocks score in neutralization tests can be due to a variety of factors, including differences in infectivity titers, methods of stock preparation, replication rate, particle/infectivity ratios, gpl20 packing density, gpl20 structure, gpl2O-gp4l affinity, gpl2O-CD4 affinity, design of the assay, and other ill-defined parameters. It has been noted previously that some strains of HIV-1 (e.g., RF) appear considerably resistant to neutralization, while others (e.g., SF2) are considerably more sensitive to neutralization (2, 28, 54 In four other studies on immune selection in humans, HIV-1 isolates were obtained which could not be neutralized by the patients' own sera, indicating that neutralizationresistant mutants had emerged in these individuals (1, 13, 31, 53) . In two of these studies (1, 53) , the neutralization assay which was used has recently been called into question. The assay, which was based on the detection of viral p24fag
protein, did not control for anti-gag antibodies which may have been present in the patients' sera. Such anti-gag antibodies can interfere with the detection of viral p249ag protein and can result in unreliable neutralization titers (5). In the other two studies (13, 31) , variant viruses were not tested against control sera to determine to what extent they were capable of being neutralized. Also, sera from individuals infected with variant virus were not available for reciprocal testing. Therefore, it is difficult to conclude from any of the four studies whether mutants specifically resistant to neutralization by the patient's sera had actually emerged in these HIV-1-infected individuals.
Rhesus monkeys infected with molecularly cloned SIV mac239 provide a useful model system for studying immune selection. More than 50% of rhesus monkeys infected with this cloned virus develop strong antibody responses to the virus and become persistently infected for 1 year or more prior to the development of AIDS (18) . By cloning viral envelope genes from rhesus monkeys over time and obtaining sequential serum samples from them, we have been able to study not only the evolution of envelope sequences but also the emergence of neutralization-resistant variants. We have also been able to infect naive monkeys with molecularly cloned variant viruses and to verify the selectivity of the neutralizing-antibody responses. In our previous study on envelope sequence variation, we found that amino acid changes in discrete segments of gpl20 result from selective forces operating in vivo (4) . Results from our present study provide strong evidence that the host neutralizing-antibody response is one of the selective forces driving sequence change in the SIV envelope and that at least some envelope variants are indeed neutralization escape mutants.
MATERIALS AND METHODS
Virus. The SIVmac239 pathogenic molecular clone and its complete sequence have been described previously (18, 19, 34, 45) . Molecular clones of env variants T69BL1-12 (variant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and T93V8-22 (variant [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] have also been described previously (4) . The (18) . Briefly, SIVmac239 provirus was subcloned into 5' left-half (p239SpSpS') and 3' right-half (p239SpE3') plasmids through the use of a unique SphI site located near the center of the viral genome (Fig. 1) . The 5' clone used in the present study was obtained from the original stock (18) . The only (no DNA) was added to 1.4 ml of DME-DEAE-dextran solution to serve as a negative control. The DME-DEAE-dextran solution containing either DNA or TE was used to resuspend 5 x 106 CEMx174 cells which had been split 24 h prior to use. The cells were incubated with the DNA solution for 40 min at 37°C. After incubation, cells were washed once with serum-free DME medium and once with serum-free RPMI 1640 medium. The cells were resuspended finally in 10 ml of complete RPMI medium. The cultures were split twice weekly at ratios of 1:2 or 1:3. The cultures were monitored visually for cytopathic effect and were tested at various intervals after transfection for the presence of viral p279ag protein by using the Coulter SIV Core Ag Assay.
Virus stocks for neutralization. Virus stocks for use in neutralization were prepared from infected CEMx174 cells approximately 9 to 13 days postinfection. Before the virus was harvested, infected cells were pelleted and the supernatant was discarded. Complete RPMI medium was added, and the infected cells were resuspended at a density of 6.0 x 105 viable cells per ml (half-maximal density for CEMx174). The virus was harvested 48 h later by clarifying the supernatant by centrifugation and filtering through 0.45-,um-pore-size filters. Virus was stored in aliquots of 0.5 to 1.0 ml in a liquid nitrogen vapor tank at approximately -150°C.
Titration of virus. All virus stocks were titered on cloned MT4 cells to determine the amount of virus to be used in the neutralization assay. Titrations were performed in 96-well plates (Falcon MicroTest III) by using serial fivefold dilutions of virus in replicates of seven. The highest dilution of virus for which all wells were positive for cell killing was selected as the amount of virus to be used for neutralization. The dilutions selected for virus stocks of SIVmac239, T69BL1-12, and T93V8-22 were 1:100, 1:50, and 1:12.5, respectively.
Cloning Fig. 2]) . The HindIII cut is upstream of the Vi region; therefore the HindIII-SstI variant env fragments contained all five variable regions of gpl20. The SstI enzyme cuts at nucleotide 9230, three amino acids upstream of the stop codon of TM (Fig. 2) ; this was the original SstI site used for cloning the PCRamplified material from the rhesus monkeys.
All Envelope sequences of molecularly cloned variants. The envelope genes of variants 1-12 and 8-22 were sequenced completely, and the deduced amino acid sequences were compared with those of the parental clone, SIVmac239 (Fig.  2) . Within the HindIII-SstI envelope fragment used for constructing the recombinants, there are 23 amino acid differences between SIVmac239 and variant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ( 18 in gpl20 and 5 in gp4l). There are 28 amino acid differences between SIVmac239 and variant 8-22 (18 in gpl20 and 10 in gp4l). This represents 96.6% amino acid identity in gp120 and 97.2 to 98.6% identity in gp4l for the variants relative to the parental clone. Variants 1-12 and 8-22 have 17 amino acid differences from each other in gp120 (96.8% identity) and 7 amino acid differences in gp4l (98.0% identity). The vast majority of amino acid substitutions and deletions in gp120 are clustered in five variable regions (Fig. 2) . In gp4l, amino acid substitutions cluster around the SF8/SE11 neutralization determinant (21) and between amino acids 792 and 804 of the cytoplasmic domain (Fig. 2) (4) . Brackets labeled "V3" LOOP and C4 refer to the V3 cysteine loop, which is variable in HIV-1 (49) and the fourth conserved region of HIV-1 which is important for CD4 binding (24) . The region marked SF8/5E11 is a weak, strain-specific neutralization determinant of SIV (21) . The signal peptide (SP) cleavage site (52) and the putative anchor domain (21) A neutralization assay based on killing of MT4 cells by uncloned SIVmac251 virus has been described previously (7) . Cloned SIVmac could not be used in this assay because the cloned virus did not kill enough MT4 cells to score in this assay. To obtain cells sufficiently sensitive to the killing effects of cloned virus, the MT4 cell line was cloned as described in Materials and Methods. One cloned cell line, called MT4 DB1-1, was used for further studies.
Virus titer determinations were performed with the cloned MT4 cells. With 300,000 cells/ml as described previously (7), complete cell killing was not achieved with the cloned MT4 cells. However, unlike the uncloned MT4 cells, cloned MT4 cells were capable of growing when seeded at low cell densities (as low as 30,000 cells per ml) with no effect on viability. When virus titer determinations were performed with cloned MT4 cells at the lower cell density of 30,000 cells per ml, complete cell killing was achieved for all three cloned viruses (parental SIVmac239, variant 1-12, and variant [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Using the appropriate dilutions for each virus, pilot neutralization tests revealed that sera from SIV-infected monkeys could neutralize cloned SIVmac and protect cloned MT4 cells from cell death. This neutralization assay was therefore used for further experiments.
Emergence of neutralization-resistant variants. By using the MTT neutralization assay, neutralization titers were determined for sequential serum samples from five SIVinfected rhesus monkeys to determine whether neutralization-resistant variants had emerged during the course of -88  12  <20  <20  <20  20  80  <20  <20  52  640  <20  <20  111  20  <20  <20  131  80  <20  <20  239 antisera, Mm206-86  12  <20  <20  <20  24  <20  <20  <20  53  320  <20  <20  85  80  <20  <20  137  20  <20  20 a p.i., postinfection.
persistent infection. All of the sera were tested against three cloned viruses (Tables 1 and 2 ). The same virus stock of each virus was used for all neutralization tests. Sequential sera from Mm243-86, infected with parental cloned SIVmac239, were found to neutralize SIVmac239 much better than they neutralized variant viruses 1-12 and [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] (Table 1 ). The variant envelopes of 1-12 and 8-22 were cloned from Mm243-86 at 69 and 93 weeks postinfection, respectively. Sera taken either around or after the time of isolation of these variant clones had detectable levels of neutralizing antibodies against the variants, whereas sera taken prior to cloning did not yield measurable neutralization titers. Thus, there appeared to be delayed neutralizingantibody responses against the variants in Mm243-86. The titers of neutralizing antibodies against variant viruses in the late-time-point sera from Mm243-86, however, never reached as high a level as against parental SIVmac239.
Sequential sera from two other animals infected with parental virus (Mml35-88 and Mm206-86) were also tested ( Table 2) . Sera from these two animals also neutralized the parental virus SIVmac239 much better than they neutralized the two variant viruses (Table 2) .
Neutralization titers of sera from Mm243-86, Mm135-88, and Mm206-86, all infected with SIVmac239, peaked at approximately 1 year postinfection and subsequently declined as the animals progressed toward AIDS (Tables 1 and  2 ). The latest serum sample from Mm243-86 was taken at the time of death from AIDS (149 weeks). The latest samples from Mm135-88 and Mm206-86 (131 and 137 weeks, respectively) were taken just before death when the animals were showing signs of AIDS.
Since neutralization titers against any particular virus are not absolute measurements in any sense, the data with sera from Mm243-86, Mm135-88, and Mm206-86 in Tables 1 and  2 other cloned viruses ( Table 1 ). The antisera from Mm2O6-89 neutralized SIVmac239 and 8-22, but neutralization was delayed and the titers were lower. Similarly, sera from Mm262-89, which was inoculated with the 8-22 virus, neutralized 8-22 better than they neutralized the other cloned viruses. The antisera from Mm262-89 also neutralized SIV mac239 and 1-12, but again neutralization was delayed and the titers were lower against these viruses. At certain time points postinfection (week 18, for example), neutralization titers of the 1-12 and 8-22 sera were as much as eightfold higher (or more) against homologous virus than against heterologous virus (Table 1) .
Neutralization titers of sera from the two animals that received variant viruses peaked slightly earlier than those of sera from the three animals that received parental virus; neutralization titers reached their highest levels by 18 to 46 weeks postinfection and had declined to lower levels after 1 year postinfection (Table 1) . Mm2O6-89 died at 66 weeks postinfection, whereas Mm262-89 is alive at 92 weeks postinfection.
Radioimmunoprecipitation. Week 37 serum from Mm243-86 and week 18 sera from Mm206-89 and Mm262-89 displayed dramatic differences in neutralization of the homologous virus versus the heterologous virus ( Table 1 ). The neutralization titer of week 37 sera against the parental virus was 80, while it was less than 20 against each of the two variant viruses. Conversely, the neutralization titer of week 18 sera against each variant virus was 160, while it was <20 against the parental virus. A radioimmunoprecipitation assay was performed to determine whether these dramatic differences in neutralization reflected differences in the ability of these sera to bind parental versus variant envelope sequences. The radioimmunoprecipitation assay revealed no significant difference in the ability of each sera to precipitate each of the three envelope proteins (Fig. 3) .
DISCUSSION
Seven recombinant clones expressing variant envelope sequences of SIVmac239 were constructed so that immune selection during persistent infection could be studied. The seven envelopes, originally isolated from Mm243-86, were selected on the basis of unique sequence differences in five variable regions in gpl20 (4 To analyze whether neutralizing-antibody responses are responsible at least in part for selecting amino acid changes in variable regions of env, it was necessary to determine neutralization titers for a variety of virus-serum combinations (Tables 1 and 2 ). One problem with comparing neutralization titers of a particular serum against three different viruses is normalization of the amount of virus. For the MTT neutralization assay, the amount of virus to be used was determined by finding the titer of the virus and taking the highest dilution of virus which repeatedly and completely induced cell killing. Therefore, the absolute amount of virus in each assay may not be the same. Differences in a variety of other parameters such as replication rate, spike density, CD4 affinity, and gpl20-gp41 affinity may also affect the neutralization process and thus influence the neutralization titers that can be obtained with different viruses. For these reasons, one-way neutralization studies, such as those with the HIV-1 system (1, 13, 31, 51, 53) , are not sufficient to prove that specific neutralization-resistant variants have emerged in individuals during persistent infection.
For the SIVmac studies described in this report, two-way "reciprocal" neutralization studies were performed. First, sera taken at various time points postinfection from three animals infected with parental SIVmac239 were tested against the three cloned viruses (Tables 1 and 2 ). Sera from all three animals neutralized SIVmac239 better than they neutralized either of the two variants. Sera taken from Mm243-86 at time points around or after the time of cloning of 1-12 and 8-22 neutralized each of the two variants, but the neutralization titers against the variants were lower than against the parental virus. For the reciprocal experiment, sera from animals infected with either 1-12 or 8-22 were used to show that each variant was neutralized best by its homologous antisera (Table 1 ). The resistance of the variants to neutralization is particularly impressive when one considers that they still share 96.6% amino acid identity in gpl20 and 97.2 to 98.6% amino acid identity in gp4l with the parental SIVmac239. Radioimmunoprecipitation analysis (Fig. 3) demonstrated that the dramatic differences in neu-J. VIROL.
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4111 tralization of the viruses were not associated with any difference in the overall anti-gp120 antibody reactivity. Therefore, if gp120 is indeed the major target of neutralizingantibody responses, neutralizing antibodies probably represent only a small fraction of the total anti-gp120 antibody population. The SIVmac immune-selection studies presented here offer the most definitive evidence to date that neutralization-resistant variants emerge in an individual during persistent infection with a primate lentivirus.
Reciprocal neutralization tests were reported in one previous EIAV study. Kono et al. (23) had previously inoculated each of five horses with five different variant viruses; the variant strains had been isolated over time from one chronically infected horse. There were delayed neutralizingantibody responses against variant strains of EIAV in the original animal, and type-specific neutralizing-antibody responses were generated in each of the five horses inoculated with variant viruses. Although some of the sera displayed a significant amount of cross-reactivity, each EIAV variant was neutralized best by its homologous antisera. Results with molecularly cloned SIVmac are similar to these early results with uncloned EIAV. The availability of cloned reagents in the SIV system will now allow us to define genetic determinants for neutralization escape and to further evaluate the selective forces operating in vivo during persistent infection. Results from this defined system should allow a clearer understanding of the role of antigenic variation and immune selection in viral persistence and the pathogenesis of AIDS.
Attempts to identify neutralization epitopes in the SIV system indicate that conformational determinants may be more important than linear determinants (15) 
